Emergent BioSolutions announced that the FDA has accepted for review its supplemental new drug application, or sNDA, for Narcan Nasal Spray, as an over-the-counter, or OTC, emergency treatment for known or suspected opioid overdose. The application has been granted priority review by the FDA and, if approved, would be the first 4 mg naloxone nasal spray available OTC in the U.S. The Prescription Drug User Fee Act goal date is March 29, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
- Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
- Biotech Alert: Searches spiking for these stocks today
- Benchmark downgrades Emergent on delay in smallpox vaccine fulfillment
- Emergent BioSolutions downgraded to Hold from Buy at Benchmark